Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
10.04
+0.96 (10.57%)
At close: Nov 21, 2025, 4:00 PM EST
10.08
+0.04 (0.40%)
Pre-market: Nov 24, 2025, 5:37 AM EST

Emergent BioSolutions Revenue

Emergent BioSolutions had revenue of $9.10M in the quarter ending September 30, 2025, a decrease of -9.00%. This brings the company's revenue in the last twelve months to $38.20M, up 22.04% year-over-year. In the year 2024, Emergent BioSolutions had annual revenue of $1.04B, down -0.54%.

Revenue (ttm)
$38.20M
Revenue Growth
+22.04%
P/S Ratio
0.69
Revenue / Employee
$876,556
Employees
900
Market Cap
527.30M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20241.04B-5.70M-0.54%
Dec 31, 20231.05B-68.20M-6.10%
Dec 31, 20221.12B-656.10M-36.99%
Dec 31, 20211.77B196.30M12.45%
Dec 31, 20201.58B471.30M42.61%
Dec 31, 20191.11B323.60M41.36%
Dec 31, 2018782.40M221.50M39.49%
Dec 31, 2017560.90M72.10M14.75%
Dec 31, 2016488.80M-531.00K-0.11%
Dec 31, 2015489.33M84.87M20.98%
Dec 31, 2014404.47M91.72M29.33%
Dec 31, 2013312.75M30.86M10.95%
Dec 31, 2012281.89M8.50M3.11%
Dec 31, 2011273.38M-12.79M-4.47%
Dec 31, 2010286.17M51.39M21.89%
Dec 31, 2009234.79M56.23M31.49%
Dec 31, 2008178.55M-4.36M-2.38%
Dec 31, 2007182.92M30.18M19.76%
Dec 31, 2006152.73M22.04M16.87%
Dec 31, 2005130.69M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
UnitedHealth Group435.16B
Johnson & Johnson92.15B
Merck & Co.64.24B
AbbVie59.64B
Eli Lilly and Company59.42B
AstraZeneca58.13B
Novartis AG56.37B
Novo Nordisk49.58B
Revenue Rankings